Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.

Lung cancer, notorious for its high mortality rates, is a leading cause of cancer-related deaths globally, with metastasis ...

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

NPG-2044 is under clinical development by Novita Pharmaceuticals and currently in Phase I for Thyroid Cancer. According to GlobalData, Phase I drugs for Thyroid Cancer have an 85% phase transition ...

Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Non-Small Cell Lung Cancer.

Thyroid autoantibody positivity was defined as TGAb levels ... This investigation revealed that patients with advanced or metastatic lung cancer demonstrated one-year and two-year OS rates of 67.0% ...

as it may lower the risk that the cancer will come back or spread. Clinical trials are being conducted on prevention and treatment options for lung cancer, including photodynamic therapy and ...

They found that these shards — which are now virtually everywhere: in the air we breathe, the water we drink and the food we eat — are suspected of links to colon cancer and lung cancer.

While treatments have significantly improved in recent decades, the biggest challenge remains: stopping cancer cells from spreading to other parts of the body, a process known as metastasis.

1Department of Experimental Zoology, MOE Key Laboratory of Environment and Genes Related to Diseases, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an, P.R. China. 2Department of ...